Clinical trials for Dendritic cell tumor
14 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPHASE1, PHASE2NCT07288112DOC1021 Dendritic Cell Immunotherapy for Refractory MelanomaDiakonos Oncology Corporation
- RECRUITINGPhase 1NCT07374029Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AMLDavid Avigan · PI: David Avigan, MD
- RECRUITINGPhase 1NCT06946615Exploratory Clinical Study of Claudin18.2-Targeted CAR-DC and CAR-T Therapy in Advanced Colorectal CancerSecond Affiliated Hospital, School of Medicine, Zhejiang University · PI: Ying Yuan
- RECRUITINGPhase 2NCT06805305DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)Diakonos Oncology Corporation
- RECRUITINGPHASE1, PHASE2NCT06253494Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerNational Cancer Institute (NCI) · PI: Hoyoung M Maeng, M.D.
- RECRUITINGPhase 1NCT05631886Combination of CAR-DC Vaccine and ICIs in Malignant TumorsChinese PLA General Hospital · PI: Yang Xu, Ph.D
- ACTIVE NOT RECRUITINGPhase 1NCT05631899CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid TumorsChinese PLA General Hospital · PI: Yang Xu, Ph.D
- RECRUITINGPhase 1NCT05504707DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast CancerH. Lee Moffitt Cancer Center and Research Institute · PI: Ricardo Costa, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05411497Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple MyelomaMayo Clinic · PI: Leif Bergsagel, M.D.
- RECRUITINGPhase 1NCT03743298Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic MelanomaAivita Biomedical, Inc. · PI: Robert O Dillman, MD
- RECRUITINGPhase 2NCT04912765Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRCNational Cancer Centre, Singapore · PI: Si Lin Koo
- RECRUITINGPhase 1NCT04157127Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic AdenocarcinomaDiakonos Oncology Corporation · PI: Benjamin Musher, MD
- RECRUITINGPHASE1, PHASE2NCT03707808Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic NivolumabUniversitair Ziekenhuis Brussel
- RECRUITINGPhase 2NCT02919644Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · PI: Francesco De Rosa, MD